N/A Completed N=14 Treatment

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

Source: ClinicalTrials.gov NCT01582945 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2017

Primary outcomePrimary: Response to Ketamine as Measured by Hamilton Depression Rating Scale -28 Items (HAMD28) — 5 participants who met response criteria

Summary

Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated. The overall aim of this study is to assess the feasibility, safety and tolerability, efficacy and duration of the effect of intravenous N-methyl-D-aspartate antagonist ketamine as augmentation of antidepressants for chronic suicidal ideation in subjects with severe treatment-resistant depression (TRD). This is an open-label study (pilot).

Outcome Measures

Outcome	Result	p-value
PRIMARY Response to Ketamine as Measured by Hamilton Depression Rating Scale -28 Items (HAMD28)	5	—

Eligibility Criteria

Inclusion Criteria

Outpatients with severe treatment-resistant MDD
Currently depressed
Currently under regular psychiatric care
On an aggressive antidepressant regimen, stable for 4 weeks

Exclusion Criteria

No history of other major psychiatric illnesses, including bipolar disorder
No history of psychosis
No history of drug abuse
No major medical illness or unstable medical conditions

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01582945). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.